Harrow, Inc. HROW

NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following three investor conferences in September in New York, NY: 2026 Cantor Global Healthcare Conference Format: Fireside chat + 1x1 investor meetingsDate/Time: Wednesday, September 9, 2026, at 1:35 p.m. ET Lake Street Capital Markets 10th Annual Best Ideas Growth Conference Format: 1

On August 10, Harrow Inc. (NASDAQ:HROW) walked investors through a first half that fell short and a back half that now has to make up the difference. Revenue for the first six months of 2026 came in around $115 million, lighter than management had expected, largely because of pricing changes tied to VEVYE. Yet the […]

Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highestNASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel)

According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30 million in cash at closing, funded via cash on hand, with up to $70 million in contingent […]

Harrow (NasdaqGM:HROW) announced the launch of BYOOVIZ in the retinal biosimilar market, adding a new product to its ophthalmology lineup. The company reported expanded formulary coverage for VEVYE, increasing potential patient access to its dry eye disease treatment. Harrow acquired TYRVAYA, further building out its portfolio focused on dry eye disease. This cluster of product moves and acquisitions around eye care is part of a wider push across healthcare, and investors who follow Harrow...

Harrow Inc (HROW) reports strong Q2 2026 with record IHISO and Vevi demand, reiterates full-year guidance, and outlines accretive Tervaya acquisition synergies.

Moby summary of Harrow Health, Inc.'s Q2 2026 earnings call

Second Quarter 2026 and Selected Highlights: Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over yearReiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure)VEVYE® delivered quarterly revenue of $29.4 million, up approximately 40% sequentially and approximately 58% year over year, with continued prescription, prescriber, and market-share growthVEVYE secured an

NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray 0.03 mg from Viatris Inc., a global healthcare company. TYRVAYA is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease (DED) and is currently approved in the U.S., China, and Taiwan,

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the second quarter ended June 30, 2026, on Monday, August 10, 2026, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional and anatomical improvements, while BCVA and CST were well maintained in patients who were switched from other anti-VEGF treatments to SB11, adding clinical confidence in using SB11 INCHEON, Korea and NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Harrow (Nasdaq: HROW

NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting IHEEZO® (chloroprocaine HCl ophthalmic gel 3%), a broadly labeled low viscosity ocular anesthetic gel, and BYOOVIZ® (ranibizumab-nuna)i, an FDA-approved biosimilar referencing LUCENTISii (ranibizumab) at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Collectiv